Patients with Huntington’s disease, a fatal genetic illness that causes the breakdown of nerve cells in the brain, have up to 80 percent less cancer than the general population.
Northwestern Medicine scientists have discovered why Huntington’s is so toxic to cancer cells and harnessed it for a novel approach to treat cancer, a new study reports.
Huntington’s is caused by an over abundance of a certain type of repeating RNA sequences in one gene, huntingtin, present in every cell. The defect that causes the disease also is highly toxic to tumor cells. These repeating sequences — in the form of so-called small interfering RNAs — attack genes in the cell that are critical for survival. Nerve cells in the brain are vulnerable to this form of cell death, however, cancer cells appear to be much more susceptible.
“This molecule is a super assassin against all tumor cells,” said senior author Marcus Peter, the Tom D. Spies Professor of Cancer Metabolism at Northwestern University Feinberg School of Medicine. “We’ve never seen anything this powerful.”
Huntington’s disease deteriorates a person’s physical and mental abilities during their prime working years and has no cure.
The study will be published Feb. 12 in the journal EMBO Reports.
To test the super assassin molecule in a treatment situation, Peter collaborated with Dr. Shad Thaxton, associate professor of urology at Feinberg, to deliver the molecule in nanoparticles to mice with human ovarian cancer. The treatment significantly reduced the tumor growth with no toxicity to the mice, Peter said. Importantly, the tumors did not develop resistance to this form of cancer treatment.
Peter and Thaxton are now refining the delivery method to increase its efficacy in reaching the tumor. The other challenge for the scientists is figuring out how to stabilize the nanoparticles, so they can be stored.
First and co-corresponding author Andrea Murmann, research assistant professor in medicine at Feinberg, also used the molecule to treat human and mouse ovarian, breast, prostate, liver, brain, lung, skin and colon cancer cell lines. The molecule killed all cancer cells in both species.
The Huntington’s cancer weapon was discovered by Murmann, who had worked with Peter on earlier research that identified an ancient kill-switch present in all cells that destroys cancer.
“I thought maybe there is a situation where this kill switch is overactive in certain people, and where it could cause loss of tissues,” Murmann said. “These patients would not only have a disease with an RNA component, but they also had to have less cancer.”
She started searching for diseases that have a lower rate of cancer and had a suspected contribution of RNA to disease pathology. Huntington’s was the most prominent.
When she looked at the repeating sequences in huntingtin, the gene that causes the disease, she saw a similar composition to the earlier kill switch Peter had found. Both were rich in the C and G nucleotides (molecules that form the building blocks of DNA and RNA).
“Toxicity goes together with C and G richness,” Murmann said. “Those similarities triggered our curiosity.”
In the case of people who have Huntington’s, the gene huntingtin has too many repeating sequences of the triplet sequence CAG. The longer the repeating sequence, the earlier they will develop the disease.
“We believe a short-term treatment cancer therapy for a few weeks might be possible, where we could treat a patient to kill the cancer cells without causing the neurological issues that Huntington’s patients suffer from,” Peter said.
Peter also is co-leader of the Translational Research in Solid Tumors Program at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.
Huntington’s patients have a lifetime exposure to these toxic RNA sequences, but generally don’t develop symptoms of the disease until age 40, he noted.
Every child of a parent with Huntington’s has 50/50 chance of carrying the faulty gene. Today, there are approximately 30,000 symptomatic Americans and more than 200,000 at-risk of inheriting the disease.
Learn more: Huntington’s disease provides new cancer weapon
The Latest on: Cancer therapy
via Google News
The Latest on: Cancer therapy
- Anchiano bails on bladder cancer gene therapy; shares down 33% premarketon November 15, 2019 at 6:19 am
Ultra-thinly traded nano cap Anchiano Therapeutics (NASDAQ:ANCN) slumps 33% premarket on light volume in reaction its decision to terminate a Phase 2 clinical trial, Codex, evaluating gene therapy ...
- Living with cancer: 'My treatment brought on the menopause at 15 and left me infertile'on November 15, 2019 at 5:40 am
They suspected an abscess, but a biopsy brought devastated news: Ellie was suffering a rare cancer of the soft tissue called alveolar rhabdomyosarcoma. The now 18-year-old had intense treatment for 18 ...
- US regulator issues first approval for a Chinese cancer treatmenton November 15, 2019 at 4:50 am
US drug regulators have issued their first ever approval for a Chinese-developed innovative cancer treatment, marking a breakthrough for the country’s biotech sector. The US Food and Drug ...
- A rationale for surgical debulking to improve anti-PD1 therapy outcome in non small cell lung canceron November 15, 2019 at 3:35 am
Immunocompetent DBA/2 mice engrafted with various amount of allogeneic lung squamous cancer KLN-205 cells were treated with anti-PD1 monoclonal antibody. Mice engrafted with two tumors also underwent ...
- Treatment with anti-cancer drug T-DM1 after pertuzumab is 'good option'on November 15, 2019 at 12:31 am
Patients with HER2-positive breast cancer, whose disease has progressed after being treated initially with pertuzumab in combination with trastuzumab and a taxane, can respond well to treatment with T ...
- Cancer Treatment Drugs Market 2019-2028 | Modern Analysis of Worldwide Competition, Strategic Development and Progressive Approachon November 14, 2019 at 11:04 pm
Nov 15, 2019 (WiredRelease via COMTEX) -- “Global Cancer Treatment Drugs Market” report includes the world’s crucial region market share, size (volume), recent trends including the product profit, ...
- Uppsala University Hospital First in Sweden to Treat Patient With Elekta Unity Cancer Treatment Systemon November 14, 2019 at 4:04 pm
UPPSALA, Sweden, Nov. 14, 2019 /PRNewswire/ -- Sweden's first-ever patient to be treated on the groundbreaking Elekta Unity MR-Linac radiation therapy system took place at Uppsala University Hospital ...
- World-first cancer therapy treats inoperable pancreas tumoron November 14, 2019 at 11:49 am
With a diagnosis of pancreas cancer, patients are often left without options. When the cancer is advanced, even surgery can be difficult or impossible. Fortunately, a first-in-the-world radiation ...
- Mom told cancer would 'eat away at your nose' without urgent treatmenton November 14, 2019 at 9:15 am
A mom in the U.K. who said she had no reason to suspect that the spot on the edge of her nose was skin cancer has been left with a bloody wound on her face that she says may take up to a year to heal ...
- Prostate cancer bone metastases thwart immunotherapy by producing TGF-betaon November 14, 2019 at 8:07 am
Prostate cancer that spreads to the bone triggers the destruction of bone tissue that, in turn, thwarts the effectiveness of immune checkpoint inhibitors by blocking the development of T cells that ...
via Bing News